Quality of life of patients with inflammatory bowel disease in the Czech Republic

Česká verze

Authors: P. Mináriková ¹ ; P. Matějková ² ; I. Kuzko ¹ ; M. Pfeiferová ³; L. Slabá ³; D. Ďuricová ^4-6 ; pacientská organizace Pacienti IBD z.s.; Pracovní skupina pro idiopatické střevní záněty ČGS ČLS JEP
Authors place of work: ÚVN, Interní klinika 1. LF UK a ÚVN Praha ¹; Gastroenterologie ResTrial, Praha ²; Pacientská organizace Pacienti IBD z. s., Praha ³; Klinické a výzkumné centrum pro střevní záněty, ISCARE a. s. a 1. LF UK, Praha ⁴; Klinika hepatogastroenterologie, IKEM, Praha ⁵; Ústav farmakologie, 1. LF UK, Praha ⁶
Published in the journal: Gastroent Hepatol 2026; 80(1): 22-29
Category: IBD: guidelines
doi: https://doi.org/10.48095/ccgh202622

Summary

Introduction: Normalization of the quality of life is an important therapeutic goal in patients with inflammatory bowel disease (IBD). Aim: To evaluate the quality of life in patients with IBD in the Czech Republic. Methods: The study involved patients with IBD aged ≥ 18 years who were approached through gastroenterology departments in the Czech Republic and online through a patient organization. Patients completed a one-time, anonymous questionnaire focusing on various aspects of the quality of life. Results: The study was conducted between September 2024 and May 2025 involving 1,272 patients (60% with Crohn‘s disease, 58% women, median age 39 years, and 60.3% on biological therapy). The most commonly reported problem associated with IBD was fatigue (82.5%), followed by gastrointestinal symptoms and extraintestinal manifestations. Up to 40% of respondents reported psychological problems (anxiety and depression). Approximately two-thirds of patients (57–69%) admitted to at least occasional restrictions in social activities such as travelling, playing sports, or eating in public places. Two-thirds of respondents (72.1%) stated that they work full-time or part-time, and 20.1% admitted to receiving disability pension. Targeted therapy –⁠ biologics and small molecules (OR 1.74; 95% CI 1.25–2.45), Crohn‘s disease (OR 1.48; 95% CI 1.09–2.03), and relapse frequency ≥ 1 per year (OR 2.73; 95% CI 2.02–3.72) increased the risk, while higher education (OR 0.48; 95% CI 0.34–0.66) reduced the risk of disability. Conclusion: This study highlighted the negative impact of IBD on various aspects of patients‘ lives, particularly their personal and professional lives, and the high incidence of mental health problems among IBD patients.

Keywords:

inflammatory bowel diseases – quality of life – Crohn’s disease – ulcerative colitis – biological products – patient reported outcome – measures – depression – employment

Zdroje

1. Ďuricová D, Pfeiferová M, Bortlík M et al. Kvalita života pacientů s idiopatickými střevními záněty v České republice –⁠ multicentrická studie. Gastroent Hepatol 2018; 72 (1): 11–19. doi: 10.14735/amgh201811.

2. Le Berre C, Ricciuto A, Peyrin-Biroulet L et al. Evolving short and long term goals of management of inflammatory bowel disease: getting it right, making it last. Gastroenterology 2022; 162 (5): 1424–1438. doi: 10.1053/ j.gastro.2021.09.076.

3. Turner D, Ricciuto A, Lewis A et al. STRIDE II: an update on selecting therapeutic target in inflammatory bowel disease (STRIDE) Initiative of International Organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160 (5): 1570–1583. doi: 10.1053/j.gastro.2020.12.031.

4. Noor N, Lee J, Bond S et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol 2024; 9 (5): 415–427. doi: 10.1016/S2468-1253 (24) 00034-7.

5. von Arnim U, Scholz K. Fatique in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2025; 78 : 102059. doi: 10.1016/j.bpg.2025.102059.

6. Barberio B, Zamani M, Black CJ et al. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systemic review and meta-analysis. Lancet Gastroenterol Hepatol 2021; 6 (5): 359–370. doi: 10.1016/S2468-1253 (21) 00014-5.

7. Gracie DJ, Hamlin PJ, Ford AC. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. Lancet Gastroenterol Hepatol 2019; 4 (8): 632–642. doi: 10.1016/S2468-1253 (19) 30089-5.

8. Burisch J, Zhao M, Odes S et al. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol 2023; 8 (5): 458–492. doi: 10.1016/S24 68-1253 (23) 00003-1.

9. Dolinger M, Torres J, Vermeire S. Crohn’s disease. Lancet 2024; 403 (10432): 1177–1191. doi: 10.1016/S0140-6736 (23) 02586-2.

10. Česká správa sociálního zabezpečení. 2025 [online]. Dostupné z: www.cssz.cz.

Poděkování

Poděkování patří všem lékařům a zdravotním sestrám z center biologické léčby IBD a ostatních gastroenterologických pracovišť, kteří povědomí o dotazníkovém šetření šířili a předávali k vyplnění pacientům.